How is factor X deficiency treated?

Updated: Feb 18, 2020
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Perumal Thiagarajan, MD  more...
  • Print

Treatment of factor X deficiency is individualized for each patient. However, restoring circulating factor X levels to 10-40% of normal is usually adequate. Additionally, in patients with acquired factor X deficiency, treatment of the underlying cause may resolve the disorder.

Therapeutic measures may include the following:

  • Factor X, human (Coagadex) is a plasma-derived human blood coagulation factor indicated in adults and children with hereditary factor X deficiency. It may be used for routine prophylaxis to reduce frequency of bleeding episodes, and can also be initiated for on-demand treatment at the first sign of a bleeding episode, at a dose of 25 IU/kg intravenously. Calculation of desired in vivo peak increase in factor X is required for precise dose. This product may also be used in patients with mild hereditary factor X deficiency to decrease bleeding risk during and after surgical procedures. [48]

  • A high-purity, plasma-derived factor X concentrate has been recommended for patients with hereditary factor X deficiency. [49]  It is well tolerated and effective in women and girls as well as in men and boys, with similar pharmacokinetics. [5]
  • Infusion of fresh frozen plasma (Octaplas) is usually sufficient to treat most hemorrhagic episodes. A loading dose of 15-20 mL/kg intravenously is administered. Because of the relatively long half-life of factor X, the loading dose can be followed by maintenance doses of 3-6 mL/kg intravenously every 12-24 hours.

  • Prothrombin complex concentrates (PCCs) have also been used to increase factor X levels. PCCs contain factors II, VII, IX, and X and protein C. PCCs should be used cautiously to avoid factor X levels of more than 50% of normal, which can result in thromboembolic episodes. Perioperative prothrombin complex concentrate has also been employed to treat acquired factor X deficiency associated with systemic light-chain amyloidosis. [50]

  • Vitamin K administration may be useful in certain patients with acquired factor X deficiency; however, it has been amply demonstrated that patients with inherited factor X deficiency do not respond to vitamin K.

Cryoprecipitate does not contain factor X and is, therefore, ineffective in factor X deficiency.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!